# AtomVie Global Radiopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atomvie-global-radiopharma

- Industry: Pharmaceuticals
- Headquarters: Canada
- Website: www.atomvie.com
- Total disclosed funding: $90M
- Latest round: Series A (Jun 1, 2023)
- Investors on record: 1

## About

Founded in 2021 and based in Ontario, Canada, AtomVie Global Radiopharma Inc. is a spinout from the CPDC (Centre for Probe Development and Commercialization) and operates as a manufacturer and distributor of radiopharmaceuticals. In June 2023, AtomVie Global Radiopharma raised USD 90 million in series A funding led by Avego Healthcare Capital. As of 2023, Bruno Paquin is the CEO of the company.

The company provides process and method development and validation; technical, regulatory, quality, logistics; clinical and commercial manufacturing; and specialized infrastructure for radiotherapeutic development from phase 1 to the commercial marketplace. The firm specializes in radiopharmaceutical manufacturing, including radiolabeling using radioisotopes such as Lu-177, Ac-225, and I-131, as well as ligands ranging from tiny compounds to peptides to small and big antibodies.

The organization plans to use the June 2023 funding to build a new facility.

## Funding rounds

- Series A, Jun 1, 2023, $90M — Avego

## Investors

- Avego (https://capitalatlas.ai/funds/avego) — Series A